Previous research identified ETS-1 as a novel therapeutic target of triple negative breast cancer (TNBC), which does not express ER, progesterone receptor (PR), or HER2 and is associated with a significant risk of poor prognosis and metastasis [11, 21]. Here, ETS1 is linked to triple-negative breast carcinoma.